HLTH vs VHT: Which Is the Better Pick in 2026?

Overview

HLTH and VHT are both healthcare-focused ETFs, but they pursue fundamentally different strategies. HLTH is an actively managed fund that concentrates on companies applying artificial intelligence across drug discovery, diagnostics, imaging, devices, and healthcare IT. VHT tracks a broad healthcare index designed to capture the US investable-market healthcare sector with modest concentration caps. The difference is not size or cost alone—it's growth-oriented thematic exposure versus diversified sector tracking.

How they differ

HLTH targets a narrower, faster-growing slice of healthcare: AI-enabled companies. VHT holds the wider healthcare sector—pharmaceuticals, biotechnology, devices, REITs, and healthcare services—weighted by market cap with index rules. That thematic focus is HLTH's core trade-off: more upside if AI transforms medicine faster than consensus prices in, but higher concentration risk and no income stream. HLTH's 0.75% fee is steeper than VHT's 0.09%, which is typical for active management but still material relative to HLTH's small asset base of $8.67M. VHT's published 0.58 suggests it moves roughly 58% as much as the broader market—a proxy for healthcare's lower volatility relative to equities overall.

Who each is best for

• HLTH: Fits investors seeking concentrated exposure to artificial intelligence within healthcare and willing to accept reinvestment risk and no current income in exchange for potential capital appreciation if AI adoption accelerates faster than the market expects.

• VHT: Fits investors wanting broad, low-cost healthcare sector exposure with modest quarterly income, a long-established fund, and lower portfolio turnover than an actively managed thematic play.

Key risks to know

• Concentration and thematic timing risk: HLTH's narrow focus on AI-enabled healthcare companies creates significant sector and valuation concentration. If market enthusiasm for healthcare AI cools or valuations compress, the fund has limited diversification within its investment universe to absorb losses.

• No track record: HLTH inception is recent enough that it has no audited performance history, making it impossible to compare how the active manager's stock-picking performs relative to benchmarks or peer funds across market cycles.

• NAV decay risk for zero-distribution funds: HLTH's lack of distributions, combined with active trading to rebalance AI exposure, may generate capital gains realizations that are not offset by dividend income, creating tax drag in taxable accounts.

• Index concentration at healthcare level: VHT's reliance on the MSCI 25/50 index rule means the largest healthcare names (typically pharma and medical device leaders) may carry outsized weight, limiting diversification benefits versus a full market-cap-weighted approach.

• Healthcare sector cyclicality: Both funds carry healthcare's exposure to regulatory risk, drug pricing pressure, and interest-rate sensitivity affecting biotech valuations. VHT's lower beta offers some downside cushion, but both are not immune to sector drawdowns.

Bottom line

If you want concentrated exposure to AI's potential in medicine and can accept reinvestment uncertainty and active management fees, HLTH's narrow thematic approach appeals to growth-oriented timing calls. If you prefer broad healthcare exposure with current income, minimal fees, and 22 years of index history, VHT's size and low cost offer stability at the cost of missing AI-specific upside. Neither is right or wrong—the choice hinges on whether you're making a thematic conviction bet or building a core holding. Past performance doesn't predict future results, and HLTH's absence of audited history makes backtested comparisons unreliable.